| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2022 | 367.29% | Chardan Capital | $7 → $5 | Maintains | Buy |
| 10/03/2022 | 834.58% | HC Wainwright & Co. | $8 → $10 | Maintains | Buy |
| 08/03/2022 | 647.66% | HC Wainwright & Co. | $14 → $8 | Maintains | Buy |
| 08/03/2022 | 460.75% | SVB Leerink | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 554.21% | Chardan Capital | $12 → $7 | Maintains | Buy |
| 03/31/2022 | 741.12% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 11/16/2021 | 1021.5% | Chardan Capital | $10 → $12 | Maintains | Buy |
| 10/12/2021 | 460.75% | Noble Capital Markets | → $6 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 367.29% | Goldman Sachs | $9 → $5 | Downgrades | Buy → Neutral |
| 07/30/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 07/06/2021 | 1208.41% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 06/03/2021 | 834.58% | Chardan Capital | $16 → $10 | Maintains | Buy |
| 10/27/2020 | 1395.33% | Chardan Capital | → $16 | Initiates Coverage On | → Buy |
| 10/26/2020 | 834.58% | SVB Leerink | → $10 | Assumes | → Outperform |
| 09/25/2020 | 1208.41% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 08/06/2020 | 834.58% | SVB Leerink | $20 → $10 | Maintains | Outperform |
| 07/31/2020 | 2236.45% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 05/28/2020 | 2516.82% | Wedbush | → $28 | Initiates Coverage On | → Outperform |
| 05/18/2020 | 1769.16% | SVB Leerink | $21 → $20 | Maintains | Outperform |
| 05/01/2020 | 834.58% | BTIG | → $10 | Initiates Coverage On | → Buy |
| 11/15/2019 | 928.04% | JP Morgan | $20 → $11 | Maintains | Overweight |
| 06/03/2019 | 1769.16% | JP Morgan | → $20 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 2236.45% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
Axcella Health Questions & Answers
The latest price target for Axcella Health (NASDAQ: AXLA) was reported by Chardan Capital on November 2, 2022. The analyst firm set a price target for $5.00 expecting AXLA to rise to within 12 months (a possible 367.29% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Axcella Health (NASDAQ: AXLA) was provided by Chardan Capital, and Axcella Health maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axcella Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axcella Health was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
While ratings are subjective and will change, the latest Axcella Health (AXLA) rating was a maintained with a price target of $7.00 to $5.00. The current price Axcella Health (AXLA) is trading at is $1.07, which is out of the analyst's predicted range.